Maps between gene identifier systems (Ensembl, Entrez, HGNC symbol, UniProt, RefSeq, MANE) using AnnotationDbi, biomaRt, mygene, pyensembl, and Ensembl REST. Encodes Ensembl version stripping with GENCODE _PAR_Y preservation, the Ziemann 2016 Excel autocorrect debacle and Bruford 2020 HGNC renames (SEPT*->SEPTIN*, MARCH*->MARCHF*, MARC*->MTARC*, DEC1->DELEC1), OCT4/POU5F1 alias resolution, biomaRt archive endpoints for release pinning, the `filters` (plural) gotcha, MANE Select for clinical reporting, cross-species orthology via Ensembl Compara / OMA / OrthoDB, and tx2gene construction for tximport. Use when converting gene IDs across systems, handling renamed symbols, building tx2gene, pinning to a specific Ensembl release for reproducibility, or mapping cross-species orthologs.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/TRACE☆ 32026年10月13日 更新
Designs genomics experiments so technical nuisance variation (batch, lane, plate, flow cell, operator, reagent lot, processing day) is balanced against the biological variable of interest and therefore estimable rather than confounded, using constrained sample-to-batch assignment (designit, OSAT), the confounder/mediator/collider distinction, and the principle that no post-hoc correction recovers a fully confounded design. Covers detecting hidden batches with surrogate variable analysis, a decision table for downstream correction (ComBat-seq, RUVSeq, SVA) whose execution is deferred to differential-expression/batch-correction, and reproducibility metadata. Use when assigning samples to sequencing batches/lanes/plates, avoiding batch-condition confounding, deciding whether a design is salvageable by correction, choosing a correction method, or estimating the number of hidden batches. For the experimental unit, randomization, and blocking concepts see experimental-design/randomization-blocking.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/TRACE☆ 32026年10月13日 更新
Structures biological experiments so inference is valid by construction, covering Fisher's principles (randomization, replication, local control), the experimental-vs-observational unit distinction and pseudoreplication (Hurlbert 1984; Lazic 2018), randomization mechanics (complete, restricted, stratified, rerandomization, run-order), blocking layouts (randomized complete block, Latin square, incomplete block), factorial designs and interactions, and the split-plot/nested error strata hidden inside multi-batch genomics. Use when deciding the experimental unit and what counts as a replicate, planning randomization and run order, choosing a blocked/factorial/split-plot/nested layout, avoiding pseudoreplication in cell-culture or animal studies, or specifying the random-effects structure of the analysis model. For assigning samples to sequencing batches/lanes/plates and batch-effect correction see experimental-design/batch-design; for regulated clinical-trial randomization see clinical-biostatistics.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/TRACE☆ 32026年10月13日 更新
Pull pre-computed ortholog calls from public databases (OrthoDB, Ensembl Compara, OMA browser, eggNOG, PANTHER, KEGG Orthology, HomoloGene) via their REST APIs. Use when orthologs are already curated upstream, when the question is "what is the X ortholog of Y" rather than "how to infer orthology de novo", when batch-mapping gene IDs across species, or when comparing the resources for consensus calls. Encodes confidence-level semantics, 1:1 vs 1:many vs many:many, HomoloGene deprecation, and when to defect to de novo computation.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/TRACE☆ 32026年10月13日 更新
Corrects the gene-independent copy-number artifact in CRISPR-Cas9 screens (Aguirre 2016 / Munoz 2016 Cancer Discov) where amplified loci appear essential from DNA-damage burden of simultaneous cuts. Covers the p53-dependent G2-arrest mechanism, CRISPRcleanR (Iorio 2018) unsupervised pre-hoc correction, CERES (Meyers 2017) joint CN + gene-effect model, Chronos (Dempster 2021) DepMap-standard population-dynamics + CN model with lowest residual bias, the decision tree by data availability, the Spearman LFC-vs-CN diagnostic, focal-amplification examples (ERBB2 in HER2+, MYC in colorectal, FGFR1 in head and neck), and CRISPRi/a alternatives that bypass the artifact. Use when screening cancer cell lines, diagnosing essentiality at amplified loci, choosing CRISPRcleanR / CERES / Chronos, deciding whether CN correction is needed before MAGeCK / BAGEL2 / drugZ, or switching from Cas9 to CRISPRi.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/TRACE☆ 32026年10月13日 更新
Performs time-to-event analysis for clinical trials including Cox proportional hazards regression with PH diagnostics, restricted mean survival time (RMST) under non-PH, competing risks via Fine-Gray vs cause-specific Cox, weighted log-rank and MaxCombo for non-proportional hazards, recurrent events (Andersen-Gill, PWP, WLW), and interval-censored data. Use when analyzing time-to-event endpoints (OS, PFS, DOR, TTR, TTNT) in oncology or other clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/TRACE☆ 32026年10月13日 更新
Queries ClinVar for variant pathogenicity classifications, ClinGen VCEP curations, and somatic-vs-germline interpretations via REST API, weekly VCF, or bulk XML. Use when determining clinical significance, triangulating conflicting interpretations, or aggregating evidence against the ACMG/AMP framework with ClinGen SVI specifications.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/TRACE☆ 32026年10月13日 更新
Performs subgroup and heterogeneous treatment effect (HTE) analyses for clinical trials. Covers Mantel-Haenszel pooling, Breslow-Day, interaction tests in regression, RERI for additive interaction, modern data-adaptive HTE methods (STEPP, SIDES, causal forests, X/R-learners), Bayesian shrinkage (Dixon-Simon, MAP, EXNEX), graphical multiplicity (Bretz-Maurer), and credibility frameworks (Sun BMJ, EMA 2019). Use when analyzing treatment effects across patient subgroups for regulatory submissions or precision-medicine claims.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/TRACE☆ 32026年10月13日 更新
Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/TRACE☆ 32026年10月13日 更新
Builds QSAR / QSPR models using chemprop D-MPNN, MolFormer, Uni-Mol, ChemBERTa, random forest baselines, and Gaussian processes with explicit handling of OECD 5 principles, applicability domain (kNN, leverage, conformal prediction, Mahalanobis), scaffold-balanced splits, ensemble uncertainty, calibration (Platt, isotonic), feature importance (SHAP, atomic attribution), and prospective validation. Use when building target-specific predictive models from in-house bioassay data, ADMET endpoints, or selectivity profiles.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/TRACE☆ 32026年10月13日 更新
Implements missing-data sensitivity analyses for confirmatory clinical trials including MMRM under MAR (with Kenward-Roger correction), reference-based multiple imputation (J2R, CR, CIR, LMCF per Carpenter-Roger 2013), Permutt delta-adjustment / tipping-point analysis, pattern-mixture identifying restrictions (CCMV, NCMV, ACMV), and the Cro vs Bartlett variance debate. Use when handling missing primary or secondary endpoint data in regulatory submissions following NRC 2010 and ICH E9(R1).
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/TRACE☆ 32026年10月13日 更新
Performs alchemical free-energy calculations including relative binding free energy (RBFE / FEP+) and absolute binding free energy (ABFE) via OpenFE, FEP+, GROMACS, AMBER pmemd, and OpenMM with explicit lambda window scheduling, soft-core potentials, REST2 enhanced sampling, MBAR/BAR analysis, and cycle closure validation. Compares ML alternatives (Boltz-2 affinity, DeepDock). Use when ranking analogs by binding affinity beyond docking accuracy, performing prospective lead optimization, or validating SAR predictions.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/TRACE☆ 32026年10月13日 更新
Performs molecular similarity searching using Tanimoto, Tversky, Dice, and cosine coefficients on bit/count fingerprints with explicit choice rules for symmetric vs asymmetric measures, scaffold-hopping vs lead-optimization regimes, activity-cliff diagnosis, and large-library nearest-neighbor methods (BulkTanimoto, Annoy MHFP6, USRCAT). Use when ranking compounds by structural resemblance to a query, clustering libraries, finding analogs, or diagnosing activity cliffs.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/TRACE☆ 32026年10月13日 更新
Generates 3D conformer ensembles using RDKit ETKDGv3 with knowledge-enhanced distance geometry, MMFF94/UFF force-field optimization, CREST + GFN2-xTB semi-empirical refinement, and macrocycle-aware torsion preferences. Provides explicit decision rules for single vs ensemble conformer use, RMSD pruning, energy windows, conformer count, and force-field choice. Use when preparing 3D ligands for docking, generating descriptor input for 3D QSAR, or sampling macrocycle/peptide conformational ensembles.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/TRACE☆ 32026年10月13日 更新
Spring Boot architecture patterns, REST API design, layered services, data access, caching, async processing, and logging. Use for Java Spring Boot backend work.
日本語の概要は準備中です。原文の説明を表示しています。
lgzarturo/springboot-course☆ 32026年10月12日 更新
Helps users discover and install agent skills when they ask questions like "how do I do X", "find a skill for X", "is there a skill that can...", or express interest in extending capabilities. This skill should be used when the user is looking for functionality that might exist as an installable skill.
日本語の概要は準備中です。原文の説明を表示しています。
lgzarturo/springboot-course☆ 32026年10月12日 更新
Build production Spring Boot applications - REST APIs, Security, Data, Actuator
日本語の概要は準備中です。原文の説明を表示しています。
lgzarturo/springboot-course☆ 32026年10月12日 更新
Build and configure Laravel 10+ applications, including creating Eloquent models and relationships, implementing Sanctum authentication, configuring Horizon queues, designing RESTful APIs with API resources, and building reactive interfaces with Livewire. Use when creating Laravel models, setting up queue workers, implementing Sanctum auth flows, building Livewire components, optimising Eloquent queries, or writing Pest/PHPUnit tests for Laravel features.
日本語の概要は準備中です。原文の説明を表示しています。
lgzarturo/springboot-course☆ 32026年10月12日 更新
FastAPI conventions for REST APIs: routers, Pydantic v2 schemas, dependency injection, error handling, pagination, and project structure. Trigger: When writing any router, endpoint, schema, or dependency in a FastAPI project.
日本語の概要は準備中です。原文の説明を表示しています。
lgzarturo/springboot-course☆ 32026年10月12日 更新
Use when building PHP applications with modern PHP 8.3+ features, Laravel, or Symfony frameworks. Invokes strict typing, PHPStan level 9, async patterns with Swoole, and PSR standards. Creates controllers, configures middleware, generates migrations, writes PHPUnit/Pest tests, defines typed DTOs and value objects, sets up dependency injection, and scaffolds REST/GraphQL APIs. Use when working with Eloquent, Doctrine, Composer, Psalm, ReactPHP, or any PHP API development.
日本語の概要は準備中です。原文の説明を表示しています。
lgzarturo/springboot-course☆ 32026年10月12日 更新
Kotlin/Spring Boot 3.x patterns - use for backend services, REST APIs, dependency injection, controllers, and service layers
日本語の概要は準備中です。原文の説明を表示しています。
lgzarturo/springboot-course☆ 32026年10月12日 更新
Use when adding hypermedia links to REST responses, building self-describing APIs, or implementing Spring HATEOAS. Use when you see EntityModel, CollectionModel, or RepresentationModel in the project.
日本語の概要は準備中です。原文の説明を表示しています。
lgzarturo/springboot-course☆ 32026年10月12日 更新
Provides expert knowledge for designing, implementing, and managing REST API versioning strategies with deprecation workflows.
日本語の概要は準備中です。原文の説明を表示しています。
lgzarturo/springboot-course☆ 32026年10月12日 更新
Amplify safe or boring designs to make them more visually interesting and stimulating. Increases impact while maintaining usability. Use when the user says the design looks bland, generic, too safe, lacks personality, or wants more visual impact and character.
日本語の概要は準備中です。原文の説明を表示しています。
waynesutton/finder9☆ 32026年5月24日 更新